Drugs / Dextran 70
Dextran 70
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00199771 | Jun 2003 → Dec 2004 | atrioventricular septal defect, congenital heart defects, multiple types, transposition of the great arteries, ventricular septal defect | Oslo University Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00316017 | May 2006 → Aug 2009 | — | University of Washington | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00570960 | Jun 2007 → Apr 2010 | infectious peritonitis | University of Virginia | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dextran 70 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00570960 ↗ |
| Known as | Dextran hm | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108451 ↗ |
| Known as | Dextran, high molecular weight | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108451 ↗ |
| Known as | Macrodex | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108451 ↗ |
| Route | Intravenous | “Subjects randomized to treatment with dextran 70 will receive it as a daily intravenous dose for the three days of the treatment protocol.” NCT00570960 ↗ |